Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

Hair regrowth in Alopecia Areata patients leads to increased satisfaction and reduced stress.

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.

JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Vitamin D analogues can significantly help hair regrowth in Alopecia Areata patients.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

Alopecia areata may be linked to changes in body fat but not to heart or artery issues.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Baricitinib is effective and safe for long-term treatment of severe alopecia areata.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.